List of Tables
Table 1. Tumor Immunotherapy Market Trends
Table 2. Tumor Immunotherapy Market Drivers & Opportunity
Table 3. Tumor Immunotherapy Market Challenges
Table 4. Tumor Immunotherapy Market Restraints
Table 5. Global Tumor Immunotherapy Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Tumor Immunotherapy Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Tumor Immunotherapy Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Tumor Immunotherapy Product Type
Table 9. Key Companies Time to Begin Mass Production of Tumor Immunotherapy
Table 10. Global Tumor Immunotherapy Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Tumor Immunotherapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Tumor Immunotherapy Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Tumor Immunotherapy Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Tumor Immunotherapy Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Tumor Immunotherapy Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Tumor Immunotherapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Tumor Immunotherapy Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Tumor Immunotherapy Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Tumor Immunotherapy Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Tumor Immunotherapy Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Tumor Immunotherapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Tumor Immunotherapy Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Tumor Immunotherapy Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Tumor Immunotherapy Sales Value by Region (2019-2024) & (%)
Table 27. Global Tumor Immunotherapy Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Tumor Immunotherapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Tumor Immunotherapy Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Tumor Immunotherapy Sales Value, (2025-2030) & (US$ Million)
Table 31. Roche Basic Information List
Table 32. Roche Description and Business Overview
Table 33. Roche Tumor Immunotherapy Products, Services and Solutions
Table 34. Revenue (US$ Million) in Tumor Immunotherapy Business of Roche (2019-2024)
Table 35. Roche Recent Developments
Table 36. Merck Basic Information List
Table 37. Merck Description and Business Overview
Table 38. Merck Tumor Immunotherapy Products, Services and Solutions
Table 39. Revenue (US$ Million) in Tumor Immunotherapy Business of Merck (2019-2024)
Table 40. Merck Recent Developments
Table 41. Novartis Basic Information List
Table 42. Novartis Description and Business Overview
Table 43. Novartis Tumor Immunotherapy Products, Services and Solutions
Table 44. Revenue (US$ Million) in Tumor Immunotherapy Business of Novartis (2019-2024)
Table 45. Novartis Recent Developments
Table 46. Johnson & Johnson Basic Information List
Table 47. Johnson & Johnson Description and Business Overview
Table 48. Johnson & Johnson Tumor Immunotherapy Products, Services and Solutions
Table 49. Revenue (US$ Million) in Tumor Immunotherapy Business of Johnson & Johnson (2019-2024)
Table 50. Johnson & Johnson Recent Developments
Table 51. GlaxoSmithKline Basic Information List
Table 52. GlaxoSmithKline Description and Business Overview
Table 53. GlaxoSmithKline Tumor Immunotherapy Products, Services and Solutions
Table 54. Revenue (US$ Million) in Tumor Immunotherapy Business of GlaxoSmithKline (2019-2024)
Table 55. GlaxoSmithKline Recent Developments
Table 56. AbbVie Basic Information List
Table 57. AbbVie Description and Business Overview
Table 58. AbbVie Tumor Immunotherapy Products, Services and Solutions
Table 59. Revenue (US$ Million) in Tumor Immunotherapy Business of AbbVie (2019-2024)
Table 60. AbbVie Recent Developments
Table 61. ELI Lilly Basic Information List
Table 62. ELI Lilly Description and Business Overview
Table 63. ELI Lilly Tumor Immunotherapy Products, Services and Solutions
Table 64. Revenue (US$ Million) in Tumor Immunotherapy Business of ELI Lilly (2019-2024)
Table 65. ELI Lilly Recent Developments
Table 66. Amgen Basic Information List
Table 67. Amgen Description and Business Overview
Table 68. Amgen Tumor Immunotherapy Products, Services and Solutions
Table 69. Revenue (US$ Million) in Tumor Immunotherapy Business of Amgen (2019-2024)
Table 70. Amgen Recent Developments
Table 71. AstraZeneca Basic Information List
Table 72. AstraZeneca Description and Business Overview
Table 73. AstraZeneca Tumor Immunotherapy Products, Services and Solutions
Table 74. Revenue (US$ Million) in Tumor Immunotherapy Business of AstraZeneca (2019-2024)
Table 75. AstraZeneca Recent Developments
Table 76. Bristol-Mysers Squibb Basic Information List
Table 77. Bristol-Mysers Squibb Description and Business Overview
Table 78. Bristol-Mysers Squibb Tumor Immunotherapy Products, Services and Solutions
Table 79. Revenue (US$ Million) in Tumor Immunotherapy Business of Bristol-Mysers Squibb (2019-2024)
Table 80. Bristol-Mysers Squibb Recent Developments
Table 81. Kite Pharma Basic Information List
Table 82. Kite Pharma Description and Business Overview
Table 83. Kite Pharma Tumor Immunotherapy Products, Services and Solutions
Table 84. Revenue (US$ Million) in Tumor Immunotherapy Business of Kite Pharma (2019-2024)
Table 85. Kite Pharma Recent Developments
Table 86. Adaptimmune Basic Information List
Table 87. Adaptimmune Description and Business Overview
Table 88. Adaptimmune Tumor Immunotherapy Products, Services and Solutions
Table 89. Revenue (US$ Million) in Tumor Immunotherapy Business of Adaptimmune (2019-2024)
Table 90. Adaptimmune Recent Developments
Table 91. Altor Bioscience Corporation Basic Information List
Table 92. Altor Bioscience Corporation Description and Business Overview
Table 93. Altor Bioscience Corporation Tumor Immunotherapy Products, Services and Solutions
Table 94. Revenue (US$ Million) in Tumor Immunotherapy Business of Altor Bioscience Corporation (2019-2024)
Table 95. Altor Bioscience Corporation Recent Developments
Table 96. Cellectis Basic Information List
Table 97. Cellectis Description and Business Overview
Table 98. Cellectis Tumor Immunotherapy Products, Services and Solutions
Table 99. Revenue (US$ Million) in Tumor Immunotherapy Business of Cellectis (2019-2024)
Table 100. Cellectis Recent Developments
Table 101. Juno Therapeutics Basic Information List
Table 102. Juno Therapeutics Description and Business Overview
Table 103. Juno Therapeutics Tumor Immunotherapy Products, Services and Solutions
Table 104. Revenue (US$ Million) in Tumor Immunotherapy Business of Juno Therapeutics (2019-2024)
Table 105. Juno Therapeutics Recent Developments
Table 106. Takara Bio Basic Information List
Table 107. Takara Bio Description and Business Overview
Table 108. Takara Bio Tumor Immunotherapy Products, Services and Solutions
Table 109. Revenue (US$ Million) in Tumor Immunotherapy Business of Takara Bio (2019-2024)
Table 110. Takara Bio Recent Developments
Table 111. Unum Therapeutics Basic Information List
Table 112. Unum Therapeutics Description and Business Overview
Table 113. Unum Therapeutics Tumor Immunotherapy Products, Services and Solutions
Table 114. Revenue (US$ Million) in Tumor Immunotherapy Business of Unum Therapeutics (2019-2024)
Table 115. Unum Therapeutics Recent Developments
Table 116. Sunway Basic Information List
Table 117. Sunway Description and Business Overview
Table 118. Sunway Tumor Immunotherapy Products, Services and Solutions
Table 119. Revenue (US$ Million) in Tumor Immunotherapy Business of Sunway (2019-2024)
Table 120. Sunway Recent Developments
Table 121. Junshi Bio Basic Information List
Table 122. Junshi Bio Description and Business Overview
Table 123. Junshi Bio Tumor Immunotherapy Products, Services and Solutions
Table 124. Revenue (US$ Million) in Tumor Immunotherapy Business of Junshi Bio (2019-2024)
Table 125. Junshi Bio Recent Developments
Table 126. Cinda Bio Basic Information List
Table 127. Cinda Bio Description and Business Overview
Table 128. Cinda Bio Tumor Immunotherapy Products, Services and Solutions
Table 129. Revenue (US$ Million) in Tumor Immunotherapy Business of Cinda Bio (2019-2024)
Table 130. Cinda Bio Recent Developments
Table 131. BeiGene Basic Information List
Table 132. BeiGene Description and Business Overview
Table 133. BeiGene Tumor Immunotherapy Products, Services and Solutions
Table 134. Revenue (US$ Million) in Tumor Immunotherapy Business of BeiGene (2019-2024)
Table 135. BeiGene Recent Developments
Table 136. Key Raw Materials Lists
Table 137. Raw Materials Key Suppliers Lists
Table 138. Tumor Immunotherapy Downstream Customers
Table 139. Tumor Immunotherapy Distributors List
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
Table 143. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Tumor Immunotherapy Product Picture
Figure 2. Global Tumor Immunotherapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Tumor Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 4. Tumor Immunotherapy Report Years Considered
Figure 5. Global Tumor Immunotherapy Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Tumor Immunotherapy Revenue in 2023
Figure 7. Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Tumor Infiltrating Lymphocyte (TIL) Treatment Picture
Figure 9. Engineered T Cell Receptor (TCR) Therapy Picture
Figure 10. Chimeric Antigen Receptor (CAR) T Cell Therapy Picture
Figure 11. Natural Killer (NK) Cell Therapy Picture
Figure 12. Other Picture
Figure 13. Global Tumor Immunotherapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Tumor Immunotherapy Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Biopharmaceutical Company
Figure 16. Product Picture of Hospital
Figure 17. Product Picture of Universities And Other Scientific Research Institutions
Figure 18. Product Picture of Other
Figure 19. Global Tumor Immunotherapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Tumor Immunotherapy Sales Value Market Share by Application, 2023 & 2030
Figure 21. North America Tumor Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 22. North America Tumor Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 23. Europe Tumor Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 24. Europe Tumor Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 25. Asia Pacific Tumor Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 26. Asia Pacific Tumor Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 27. South America Tumor Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 28. South America Tumor Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 29. Middle East & Africa Tumor Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 30. Middle East & Africa Tumor Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 31. Key Countries/Regions Tumor Immunotherapy Sales Value (%), (2019-2030)
Figure 32. United States Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 33. United States Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 34. United States Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 35. Europe Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 36. Europe Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 37. Europe Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 38. China Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 39. China Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 40. China Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 41. Japan Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 42. Japan Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 43. Japan Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 44. South Korea Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 45. South Korea Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 46. South Korea Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 47. Southeast Asia Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 48. Southeast Asia Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 49. Southeast Asia Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 50. India Tumor Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 51. India Tumor Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 52. India Tumor Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 53. Tumor Immunotherapy Industrial Chain
Figure 54. Tumor Immunotherapy Manufacturing Cost Structure
Figure 55. Channels of Distribution (Direct Sales, and Distribution)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
